Skip to main content
Equibles
BICX logo

BICX · BioCorRx Inc. · Metrics

Track BICX — free

Use BICX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BICX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.24 At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had cash of $21,237 and working capital deficit of $8,231,326. During the six months ended June 30, 2026, the Company used net cash in operating activities of $873,260. The Company has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued.”
View the 10-Q filed Aug 14, 2026
Customer concentration — top 2 customers 100% of revenue

2 customers — 100% of revenue (three months ended June 30, 2026)

“The Company's revenues earned from sale of products and services for the three months ended June 30, 2026 included 100% from two customers of the Company's total revenues.”

2 customers — 99% of revenue (three months ended June 30, 2025)

“The Company's revenues earned from sale of products and services for the three months ended June 30, 2025 included 99% from two customers of the Company's total revenues.”
View the 10-Q filed Aug 14, 2026
Market Cap
$7.44M
Shares
29.76M
Volume · Oct 20 1000 Avg daily vol (3M) 3256

BICX metrics

55 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.24
Market cap
$7.44M

Price action

20 metrics
Price change (1W)
-3.9%
Price change (30D)
+19.5%
Price change (3M)
-3.9%
Price change (6M)
-41.0%
Price change (YTD)
-17.5%
Price change (1Y)
-40.0%
Trailing year
Price change (5Y)
-91.4%
52-week high
$0.50
52-week low
$0.16
Change from 52-week high
-51.5%
Change from 52-week low
+50.0%
Annualized volatility
286.0%
Annualized volatility (3M)
—
Beta
-0.6
RSI (14D)
50.6
Price vs SMA 50
-11.3%
Price vs SMA 200
-28.7%
Avg volume (3M)
3,256
Relative volume
0.3
Average dollar volume
$794

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
29.76M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.5×
reciprocal yield 10.6%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-42.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-623.1%
Trailing 12 months
Net margin
-400.6%
Gross profit (TTM)
$183,109
Operating profit (TTM)
−$4.90M
Net income (TTM)
−$3.15M
Trailing 12 months
Diluted EPS (TTM)
$-0.12
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.46

Growth

11 metrics
Revenue growth YoY
-50.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$786,616
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+71.8%
Year over year · more shares
Revenue CAGR (3Y)
+55.1%
Revenue CAGR (5Y)
+45.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-165.2%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$5.08M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-30.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$21,237
Total assets
$1.91M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.36M
Capital expenditures (TTM)
—
R&D (TTM)
$2.37M
SG&A (TTM)
$3.15M
Stock compensation (TTM)
$516,266
R&D / revenue
301.9%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 11.7 days to cover
Days to cover
11.7d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1443863 CUSIP 09073C205 Visit website Investor relations